Exact Mass: 614.3639
Exact Mass Matches: 614.3639
Found 375 metabolites which its exact mass value is equals to given mass value 614.3639
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Toxiferine
D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
CHAPS
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids D013501 - Surface-Active Agents > D003902 - Detergents
Antibiotic X 14889C
Ruminant feed additive. Ruminant feed additive
(6S,3'S,5'R,6'R)-6,3',5'-Trihydroxy-4,5,6',7'-tetradehydro-7,8,5',6'-tetrahydro-beta,beta-carotene-3,8-dione
Chaps
4-[4-[(2R,5R)-5-[2-(Dibenzylamino)-2-oxoethyl]-2-heptyl-4-oxo-1,3-thiazolidin-3-yl]butyl]benzoic acid
PA(8:0/PGJ2)
PA(8:0/PGJ2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/PGJ2), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of Prostaglandin J2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGJ2/8:0)
PA(PGJ2/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGJ2/8:0), in particular, consists of one chain of one Prostaglandin J2 at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
(2R,2R,3S,3R)-2,2,3,3-Tetrahydroxy-beta,beta-caroten-4-one
Amarouciaxanthin A
D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids Window width to select the precursor ion was 3 Da.; CONE_VOLTAGE was 10 V.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan. Window width to select the precursor ion was 3 Da.; CONE_VOLTAGE was 20 V.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.
(4alpha,6alpha,7alpha,17alpha,20S,23R,24E)-2,3,5,6-tetrahydro-7,23,26-trihydroxy-6-p-methoxyphenyl-13,30-cyclo-29-nordammara-2,11,24-trieno[4,3-c]pyran-21-oic acid gamma-lactone|dichapetalin K
3beta-hydroxyresiniferonol-6alpha,7alpha-epoxy-9,13,14-ortho-2E-hexadecenoate|synaptolepsis factor K7
kurilensoside H
Tri-Ac-(3beta,15alpha,16alpha)-3,15,16-Trihydroxy-12-oleanen-28-oic acid
(19E,17S,19E)-1-acetyl-17,17-epoxy-(16betaH)-[1,17]bicuranyl-19,19-diene|Isostrychnobilin|isostrychnobiline
3-O-alpha-L-rhamnopyranosyl-(1<*>2)-beta-D-glucopyranosyl-(13E)-labda-8(17),13-diene-3beta,15-diol|3-O-alpha-L-rhamnopyranosyl-(1[*]2)-beta-D-glucopyranosyl-(13E)-labda-8(17),13-diene-3beta,15-diol
12-hydroxyabieta-8,11,13-trien-7beta-yl 6-hydroxy-7-oxoabieta-5,8,11,13-tetraen-12-yl peroxide|obtusanol B
2beta,3beta-Diacetoxy-Delta12-oleanen-23,28-disaeuredimethylester|2beta,3beta-Diacetoxy-olean-12-en-23,28-disaeure-dimethylester|2beta,3beta-diacetoxy-olean-12-ene-23,28-dioic acid dimethyl ester|2beta,3beta-Diacetoxyolean-12-en-23,28-bissaeure-methylester|acide medicagenique diacetate dimethyl ester|diacetate dimethylester de lacide medicagenique|diacetate du methylester de lacide medicanique
13beta-ent-3,14-clerodadien 6alpha-O-beta-D-quinovopyranosyl-13-O-beta-D-glucopyranoside
(1S,3R,4S,4aR,8aR)-1,2,3,4,4a,5,6,8a-octahydro-4-[(3S)-3-hydroxy-3-methylpent-4-en-1-yl]-3,4,8,8a-tetramethylnaphthalen-1-yl 6-deoxy-4-O-beta-D-glucopyranosyl-alpha-L-mannopyranoside|(6S,13S)-6-{[beta-D-glucopyranosyl-(1->4)-alpha-L-rhamnopyranosyl]oxy}cleroda-3,14-dien-13-ol
18-O-alpha-L-rhamnopyranosyl-(1<*>2)-beta-D-glucopyranosyl-13-epitorreferol
1,2-dihydro-5beta-hydroxy-21-methyl-6alpha,7alpha-epoxy-9,13,14-ortho-1alpha-(33E-pentadecenoate)-resiniferonol-36-oic acid|kirkinine B
3beta-[(E)-3-(4-methoxyphenyl)acryloxy]urs-11-en-28,13beta-olide|ehretiolide
3-O-beta-D-glucopyranosyl-13-O-alpha-L-rhamnopyranosyl-3beta-hydroxymanool
(1S,3R,4S,4aR,8aR)-1,2,3,4,4a,5,6,8a-octahydro-4-[(3E)-5-hydroxy-3-methylpent-3-en-1-yl]-3,4,8,8a-tetramethylnaphthalen-1-yl 6-deoxy-4-O-beta-D-glucopyranosyl-alpha-L-mannopyranoside|(6S,13E)-6-{[beta-D-glucopyranosyl-(1->4)-alpha-L-rhamnopyranosyl]oxy}cleroda-3,13-dien-15-ol
3-O-alpha-L-rhamnopyranosyl-(1<*>2)-beta-D-glucopyranosyl-3beta-hydroxy-13-epimanool
12xi-acetoxy-11beta-hydroxypetuniasterone M 7-acetate
16beta-hydroxy-ent-kauran-19-oic acid 19-[alpha-L-arabinopyranosyl-(1->2)-beta-D-glucopyranosyl] ester
(6S,13S)-6-O-alpha-L-rhamnopyranosyl-(1<*>2)-beta-D-glucopyranosyl-6,13-dihydroxycleroda-3,14-diene|(6S,13S)-6-O-alpha-L-rhamnopyranosyl-(1[*]2)-beta-D-glucopyranosyl-6,13-dihydroxycleroda-3,14-diene|(6S,13S)-cleroda-3,14-diene-6,13-diol 6-O-alpha-L-rhamnopyranosyl-(1-2)-beta-D-glucopyranoside|alpha-vinyl-1,2,3,4,4a,7,8,8a-octahydro-alpha,1,2,4a,5-pentamethyl-1-naphthalenepropanol 4-O-alpha-rhamnopyranosy-(1-2)-beta-glucopyranoside
2alpha,3beta,23-triacetoxyurs-12-ene-28-oic acid|2alpha,3beta,23alpha-Triacetoxy-urs-12-en-28-oic acid|2alpha.3beta.23-triacetoxy-ursen-(12)-oic acid-(28)|2alpha.3beta.23-Triacetoxy-ursen-(12)-saeure-(28)|asiatic acid triacetate|triacetylasiatic acid
(25S)-3-O-(2-O-methyl-beta-D-xylopyranosyl)-5alpha-cholestane-3beta,4beta,8,15alpha,16beta,26-hexol|kurilensoside E
(20R,24S)-24-O-(beta-D-glucopyranosyl)-5alpha-cholestan-3beta,6alpha,8,15beta,24-pentaol|(20R,24S)-24-O-(beta-D-glucopyranosyl)-5alpha-cholestane-3beta,6alpha,8,15beta,4-pentaol|evasterioside D
Phe His Arg Arg
Phe Arg His Arg
Phe Arg Arg His
His Phe Arg Arg
His Arg Phe Arg
His Arg Arg Phe
Lys Arg Arg Arg
Gln Arg Arg Arg
Arg Phe His Arg
Arg Phe Arg His
Arg His Phe Arg
Arg His Arg Phe
Arg Lys Arg Arg
Arg Gln Arg Arg
Arg Arg Phe His
Arg Arg His Phe
Arg Arg Lys Arg
Arg Arg Gln Arg
Arg Arg Arg Lys
Arg Arg Arg Gln
Evasterioside D
Kurilensoside E
Hellebrigenin-3-(12-hydroxy-laurate)
ST 35:7;O9
(3R,3R,5S)-3,3,5,19-tetrahydroxy-7,8-didehydro-gamma,epsilon-carotene-8-one
PHORBOL, 20-OXO-20-DEOXY 12-MYRISTATE 13-ACETATE, 4BETA
Carbenoxolone sodium
A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) C471 - Enzyme Inhibitor > C54678 - Hydroxysteroid Dehydrogenase Inhibitor D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents
1,2-Dimyristoyl-sn-glycero-3-phosphate (sodium salt)
SLIGKV-NH2
Protease-Activated Receptor-2, amide (SLIGKV-NH2) is a highly potent protease-activated receptor-2 (PAR2) activating peptide.
trimethyl-[(2S,3R,4S,5R)-1,2,4,5,6-pentakis(trimethylsilyloxy)hexan-3-yl]oxysilane
4-[4-[(2R,5R)-5-[2-(Dibenzylamino)-2-oxoethyl]-2-heptyl-4-oxo-1,3-thiazolidin-3-yl]butyl]benzoic acid
(6S,3S,5R,6R)-6,3,5-Trihydroxy-4,5,6,7-tetradehydro-7,8,5,6-tetrahydro-beta,beta-carotene-3,8-dione
D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids
Acetyl Podocarpic Acid Anhydride
Acetyl podocarpic acid anhydride is a potent, semisynthetic liver X receptor(LXR) agonist derived from extracts of the mayapple. Acetyl podocarpic acid anhydride has the potential to be useful for the prevention and research of atherosclerosis, especially in the context of low HDL levels[1].
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide
1-cyclohexyl-3-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]urea
1-cyclohexyl-3-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]urea
1-cyclohexyl-3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]urea
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide
1-cyclohexyl-3-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]urea
1-cyclohexyl-3-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]urea
1-cyclohexyl-3-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]urea
1-cyclohexyl-3-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]urea
methyl (1R,4R,7S,14R,20R,21S,24E,25S,26S,38S,39R)-24-ethylidene-39-methyl-3,11,22,27-tetrazadodecacyclo[20.11.2.13,15.14,7.17,11.121,25.01,20.04,14.020,27.028,33.014,38.019,37]nonatriaconta-15(37),16,18,28,30,32-hexaene-26-carboxylate
[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] nonadecanoate
[(2R)-1,1,3,3-tetradeuterio-2-hydroxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] nonadecanoate
[1-octanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[1-butanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
[1-acetyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate
[1-propanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate
[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-hexanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
[1-[(2-heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
(1-octanoyloxy-3-phosphonooxypropan-2-yl) (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
(1-decanoyloxy-3-phosphonooxypropan-2-yl) (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-phosphonooxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
(1-dodecanoyloxy-3-phosphonooxypropan-2-yl) (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
(1-phosphonooxy-3-tetradecanoyloxypropan-2-yl) (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-carboxy-3-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-2-decanoyloxy-3-phosphonooxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate
[(2R)-2-decanoyloxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-1-decanoyloxy-3-phosphonooxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate
(1-phosphonooxy-3-tetradecanoyloxypropan-2-yl) (9E,11E,13E)-hexadeca-9,11,13-trienoate
[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate
[1-carboxy-3-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]propyl]-trimethylazanium
[1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate
[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate
[(2R)-1-decanoyloxy-3-phosphonooxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate
2-[[3-butanoyloxy-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-hexanoyloxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-acetyloxy-2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-octanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
1,2-(8R,9R-epoxy-octadec-13Z,15Z-dien-4,6-diynoyl)-sn-glycerol
Palmitoyl Tripeptide-1 (hydrochloride)
Palmitoyl tripeptide-1 hydrochloride is a fatty acid modified polypeptide. Palmitoyl Tripeptide-1 has good wrinkle-removing effect[1].
VKGILS-NH2
VKGILS-NH2 is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 has no effect on DNA synthesis in cells[1][2].
(2e)-4-[(1s,2s,13s,15r)-7-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-17,17-dimethyl-5-(3-methylbut-2-en-1-yl)-10,14-dioxo-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraen-15-yl]-2-methylbut-2-enal
(4ar,5s,6as,6br,8ar,9r,10s,12ar,12br,14bs)-5,10-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid
5-(acetyloxy)-6-[3,7-bis(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid
2-[(2e)-1-{[(1s)-1-carboxy-2-(1h-indol-3-yl)ethyl]-c-hydroxycarbonimidoyl}-10-oxoheptadec-2-en-1-yl]-2-hydroxybutanedioic acid
15-(7-hydroxy-6-methylheptan-2-yl)-2,16-dimethyl-5-[(3,4,5-trihydroxyoxan-2-yl)oxy]-7-oxapentacyclo[9.7.0.0²,⁸.0⁶,⁸.0¹²,¹⁶]octadecane-9,11,13,14-tetrol
n-[2-({[(1r,2r,3r,4s,5s,6s,8r,9s,10r,13s,16s,17r,18s)-11-ethyl-4,8,9-trihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid
(1r,3r,3as,3bs,5r,5as,6r,7s,9as,9br,11ar)-7-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-1-[(2r,5s)-5-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,6-tetrol
{6-[7-(acetyloxy)-1-hydroxy-3a,6,6,9a,11a-pentamethyl-2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2,3-dihydroxy-2-methylheptyl}oxysulfonic acid
(1s,2r,4r,12s,18r)-14,14,18-trimethyl-5-[(1r,12r,15s,17s)-1,14,14-trimethyl-19-oxo-9,13-diazapentacyclo[13.2.2.0²,¹⁰.0³,⁸.0¹²,¹⁷]nonadeca-2(10),3,5,7-tetraen-7-yl]-5,13-diazahexacyclo[13.3.1.0²,¹³.0⁴,¹².0⁴,¹⁸.0⁶,¹¹]nonadeca-6,8,10-trien-16-one
2,4a-dimethyl (2s,4ar,6as,6br,8as,10r,11s,12ar,12bs,14bs)-10,11-bis(acetyloxy)-2,6a,6b,9,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-2,4a-dicarboxylate
(2s,3r,4s,5s,6r)-2-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4s,4ar,8ar)-4-[(3s)-3-hydroxy-3-methylpent-4-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
n-[2-({[(1r,2r,3r,4s,5s,6s,8r,9s,10r,16s,18s)-11-ethyl-4,8,9-trihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid
(2e,5s,6s)-6-[(1r,3s,3ar,5ar,7s,9as,11ar)-3,7-bis(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid
(1s,4s,5s,8r,9r,12r,13s,16s)-5,9,17,17-tetramethyl-8-[(2r,4e)-6-methylhepta-4,6-dien-2-yl]-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-18-oxapentacyclo[10.5.2.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-2-en-19-one
(1r,4s,5s,8r,9r,12s,13s,16s)-5,9,17,17-tetramethyl-8-[(2r,4e)-6-methylhepta-4,6-dien-2-yl]-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-18-oxapentacyclo[10.5.2.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-2-en-19-one
(1s,2r,4r,12s,18r)-14,14,18-trimethyl-10-[(1s,2r,4r,15s,18r)-14,14,18-trimethyl-16-oxo-5,13-diazahexacyclo[13.3.1.0²,¹³.0⁴,¹².0⁴,¹⁸.0⁶,¹¹]nonadeca-6,8,10-trien-5-yl]-5,13-diazahexacyclo[13.3.1.0²,¹³.0⁴,¹².0⁴,¹⁸.0⁶,¹¹]nonadeca-6,8,10-trien-16-one
(9-hydroxy-5a,10b-dimethyl-3-{1,6,7,11,11-pentamethyl-2-oxatricyclo[8.4.0.0³,⁷]tetradecan-6-yl}-1h,2h,3h,3ah,4h,5h,10h,10ah-cyclopenta[a]fluoren-6-yl)oxidanesulfonic acid
[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16r,17r,18s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-aminobenzoate
3beta,16beta,23-triacetoxyolean-12-en-28-oic acid
{"Ingredient_id": "HBIN008033","Ingredient_name": "3beta,16beta,23-triacetoxyolean-12-en-28-oic acid","Alias": "3beta,16beta,23-triacetoxyolean-12-en-28-oic acid","Ingredient_formula": "C36H54O8","Ingredient_Smile": "CC(=O)OCC1(C2CCC3(C(C2(CCC1OC(=O)C)C)CC=C4C3(CC(C5(C4CC(CC5)(C)C)C(=O)O)OC(=O)C)C)C)C","Ingredient_weight": "614.8 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9988;9989;16252","PubChem_id": "11387939","DrugBank_id": "NA"}